Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress – Yahoo Finance

CAMBRIDGE, Mass., September 23, 2021–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations as part of the World Muscle Society (WMS) Virtual Congress taking place September 20-24, 2021.
Details for the virtual posters at the WMS meeting are as follows:
Title (late breaker): Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (LBP.10)
This late breaking poster presentation will feature multiple efficacy endpoints, including Hammersmith scales and Revised Upper Limb Module (RULM) function, from the 12-month TOPAZ Phase 2 trial evaluating apitegromab in patients with Type 2 and 3 Spinal Muscular Atrophy (SMA).
An additional exploratory analysis evaluating time to achieving various thresholds of improvement in Hammersmith Functional Motor Scale Expanded (HFMSE) scores further support the dose response in clinical efficacy.
Increases in RULM were also observed in both non-ambulatory cohorts.
Greater increases in HFMSE (non-ambulatory) and Revised Hammersmith Scale (ambulatory) scores were seen in patients who were not limited by scoliosis or joint contractures.
Title: Insights into the Potential Pharmacological Effects of Apitegromab in Health and Disease: Data from Preclinical and Clinical Studies (EP.277)
The poster will showcase insights into the target engagement and exposure levels of apitegromab in the TOPAZ trial as well as from Phase 1 healthy volunteer and preclinical studies.
Virtual poster presentations (LBP.10 and EP.277) on September 23, 2021, at 16:30-18:30 BST
E-Posters available to view on demand and exhibition area open starting Monday, September 20, 2021.
"These additional analyses from the TOPAZ Phase 2 trial further reinforce our enthusiasm for the potential of apitegromab to improve motor function for patients with SMA, and provide exploratory insights in both the ambulatory and non-ambulatory populations," said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. "We anticipate initiating a Phase 3 trial to evaluate apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA by the end of 2021 as we work towards our aim of establishing apitegromab as the potential first muscle-directed therapy to treat SMA."
About Apitegromab
Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track (FTD), Orphan Drug (ODD) and Rare Pediatric Disease (RPD) designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any use by the FDA or any other regulatory agency.
About SMA
Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in the United States and Europe. It is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. The underlying pathology of SMA is caused by insufficient production of the SMN (survival of motor neuron) protein, essential for the survival of motor neurons, and is encoded by two genes, SMN1 and SMN2. While there has been progress in the development of therapeutics that address the underlying SMA genetic defect, via SMN-dependent pathways, there continues to be a high unmet need for therapeutics that directly address muscle function.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development timing, its cash runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include preclinical and clinical data, including the 12-month top-line results from the Phase 2 trial of apitegromab, are not predictive of, are inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including the planned Phase 3 trial of apitegromab in SMA, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock’s current and potential future collaborations, including its collaboration with Gilead, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
View source version on
Scholar Rock:
Catherine Hu
[email protected]

Ariane Lovell
Finn Partners
[email protected]
Related Quotes
The European Medicines Agency (EMA) aims to decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course, saying breakthrough infections added some urgency to its review. "The outcome of this evaluation is expected in early October, unless supplementary information is needed," EMA's head of vaccines strategy, Marco Cavaleri, told a press briefing on Thursday.
The U.S. vaccination drive against COVID-19 stands on the verge of a major new phase: Government advisers on Thursday recommended booster doses of Pfizer’s vaccine for millions of Americans.
The company is still working to submit its vaccine candidate to U.S. authorities for federal approval.
Axsome Therapeutics (NASDAQ: AXSM) is close to earning approval for a new depression drug that could generate billions in annual revenues. Unfortunately, the proposed action date for the Food and Drug Administration (FDA) to grant approval already came and went. Consensus price targets suggest Axsome Therapeutics' stock price could rise 197% if most investors begin seeing the company in the same light as the investment-bank analysts who follow it closely.
Shares of Cassava Sciences (NASDAQ: SAVA) — the biotech company responsible for Alzheimer's drug candidate simufilam — are up 15% as of Thursday's market close after the company released interim data from a study funded by the National Institutes of Health. According to management, data from the first 50 patients to receive treatment, who had mild to moderate Alzheimer's, showed improved cognition scores after 12 months. The fireworks started after law firm Labaton Sucharow filed a citizen petition with the Food and Drug Administration.
The past month has been fraught with debate over who should be allowed to get boosters, and the messaging changed with each new step causing confusion among experts.
The CDC overruled its own panel Friday, endorsing booster shots for elderly and otherwise vulnerable adults. But vaccine stocks dipped.
Oral antiviral treatments for Covid-19 could give a public health boost and generate blockbuster sales for the drug industry.
Lilly's experimental Alzheimer's therapy, donanemab, still has a “transformational growth opportunity,” despite Biogen's embattled rollout of Aduhelm, says J.P. Morgan Christ Schott.
Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Friday after the World Health Organization recommended its monoclonal antibody as a treatment for COVID-19. The global body says the combination treatment can be used in COVID-19 patients who are at high risk of severe disease as well as in severe and critically ill COVID-19 patients who have not yet developed antibodies. The therapy has generated $3.5 billion in revenue in the first half of 2021. "WHO also calls for
Matthew Trunsky is used to people being angry at him. As a pulmonologist and director of the palliative care unit at a Beaumont Health hospital in southeastern Michigan, Trunsky sees some of the facility's sickest patients and is often the bearer of bad news.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. He gets it. No one is prepared to hear their loved one is dying. But when a well-regarded intensive care unit nurse told him durin
The increasing number of at-home testing kits for COVID-19 makes it convenient to test for COVID-19, plus considerably safer than risking exposure by going for testing at a public location. However, a group of infectious disease researchers have discovered that for someone who actually wants a positive COVID-19 test result, getting it may be as easy as stopping by a convenience store's beverage cooler.A group of scientists studying tropical medicine at Germany's Tübingen University recently publ
"The outcome of this evaluation is expected in early October, unless supplementary information is needed," EMA's head of vaccines strategy, Marco Cavaleri, told a press briefing on Thursday. Cavaleri's statement confirmed a Reuters report earlier in the day on EMA's expected review time on the matter. The U.S. Food and Drug Administration on Wednesday authorized a third dose of Pfizer for those aged 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the coronavirus.
Some of the nation's most aggressive COVID-19 vaccine mandates are scheduled to take effect Monday in New York amid continued resistance from some to the shots, leaving hospitals and nursing homes across the state and schools in New York City bracing for possible staff shortages.
Novavax Inc and its partner Serum Institute of India have applied to the World Health Organization for an emergency use listing of Novavax's COVID-19 vaccine, potentially clearing the way for the shot to ship to many poorer countries, the company said on Thursday. Novavax has been prioritizing regulatory submissions to low- and middle-income countries after falling behind in the race for authorization in the United States and Europe, which have already vaccinated most of their residents. A WHO listing would allow Novavax to ship to multiple developing nations that rely on WHO guidance for their regulatory decisions.
Our 2021 healthcare roundtable highlights the technologies and treatments changing the face of medicine, and the companies that could benefit.
A CDC advisory panel voted Thursday to recommend COVID-19 boosters of the Pfizer/BioNTech vaccine for a broad population of U.S. residents. The CDC released guidance that overruled the panel.
Forceful words don't always result in strong action. AP Photo/Damian DovarganesAre workplace vaccine mandates prompting some employees to quit rather than get a shot? A hospital in Lowville, New York, for example, had to shut down its maternity ward when dozens of staffers left their jobs rather than get vaccinated. At least 125 employees at Indiana University Health resigned after refusing to take the vaccine. And several surveys have shown that as many as half of unvaccinated workers insist th
Moderna Inc Chief Executive Stéphane Bancel thinks the coronavirus pandemic could be over in a year as increased vaccine production ensures global supplies, he told the Swiss newspaper Neue Zuercher Zeitung. The price of vaccination will stay the same, he said.
"The shot took me from death," Rev. Jesse Jackson said.